Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.
Courtney Woolsey, Joan B Geisbert, Demetrius Matassov, Krystle N Agans, Viktoriya Borisevich, Robert W Cross, Daniel J Deer, Karla A Fenton, John H Eldridge, Chad E Mire, Thomas W Geisbert
Author Information
Courtney Woolsey: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Joan B Geisbert: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Demetrius Matassov: Department of Virology and Vaccine Vectors, Profectus BioSciences, Pearl River, New York.
Krystle N Agans: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Viktoriya Borisevich: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Robert W Cross: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Daniel J Deer: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Karla A Fenton: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
John H Eldridge: Department of Virology and Vaccine Vectors, Profectus BioSciences, Pearl River, New York.
Chad E Mire: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
Thomas W Geisbert: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.
A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.
